Literature DB >> 26238864

Azithromycin is not associated with QT prolongation in hospitalized patients with community-acquired pneumonia.

Lee Hilary Goldstein1,2,3, Ahmad Gabin1, Abdallah Fawaz1, Nahum Adam Freedberg2,4, Naama Schwartz5,6, Mazen Elias1,2, Walid Saliba1,2.   

Abstract

PURPOSE: Large data-based studies have reported excess cardiovascular mortality in high-risk patients treated with azithromycin, but whether or not azithromycin causes QT prolongation remains controversial. The purpose of this study was to examine the association of azithromycin treatment on QT prolongation in a cohort of patients hospitalized with community-acquired pneumonia (CAP)
METHODS: One-hundred twenty-two hospitalized patients with CAP were enrolled in the study. We compared the baseline QTc, with daily post antibiotic QTc. Other risk factors for QT prolongation such as medication or electrolyte abnormalities were recorded.
RESULTS: Ninety (73.8%) patients were treated with azithromycin (usually in combination with ceftriaxone), and 32 (26.2%) patients with other antibiotics (ampicillin-clavulanate, chloramphenicol, doxcycline, or ceftriaxone); 72.1% (88) of the cohort experienced QT lengthening; 72.7% with QT lengthening had a normal baseline QTc. Azithromycin was not associated with the post-antibiotic QTc. Wide (pathological) post-antibiotic QTc was associated with the pneumonia score. Every 10-point increase in the pneumonia score raised the risk for a pathological post antibiotic QTc by 1.249 (95%CI: 1.050-1.486). Analysis of patients with non-pathological baseline QTc revealed that pathological post-antibiotic QTc was only associated with previous stroke and not with the type of antibiotic.
CONCLUSIONS: Azithromycin treatment was not associated with QT prolongation in patients with severe CAP. Nonetheless, in a large majority of hospitalized CAP patients, QT prolongation and pathological QTc develop regardless of the antibiotic used, especially in patients with previous stroke or a higher pneumonia score.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  QT prolongation; azithromycin; hospitalization; macrolides; pharmacoepidemiology; pneumonia

Mesh:

Substances:

Year:  2015        PMID: 26238864     DOI: 10.1002/pds.3842

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  4 in total

1.  Systematic Review, Meta-analysis, and Network Meta-analysis of the Cardiovascular Safety of Macrolides.

Authors:  Mordechai Muszkat; Ilan Matok; Einat Gorelik; Reem Masarwa; Amichai Perlman; Victoria Rotshild
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

2.  Lethal Synergism between Influenza and Streptococcus pneumoniae.

Authors:  Jennifer M Rudd; Harshini K Ashar; Vincent Tk Chow; Narasaraju Teluguakula
Journal:  J Infect Pulm Dis       Date:  2016-04-30

3.  Risk Evaluation of Azithromycin-Induced QT Prolongation in Real-World Practice.

Authors:  Young Choi; Hong-Seok Lim; Dahee Chung; Jung-Gu Choi; Dukyong Yoon
Journal:  Biomed Res Int       Date:  2018-10-14       Impact factor: 3.411

4.  QT Interval Prolongation Under Hydroxychloroquine/Azithromycin Association for Inpatients With SARS-CoV-2 Lower Respiratory Tract Infection.

Authors:  Sok-Sithikun Bun; Philippe Taghji; Johan Courjon; Fabien Squara; Didier Scarlatti; Guillaume Theodore; Delphine Baudouy; Benjamin Sartre; Mohamed Labbaoui; Jean Dellamonica; Denis Doyen; Charles-Hugo Marquette; Jacques Levraut; Vincent Esnault; Sok-Siya Bun; Emile Ferrari
Journal:  Clin Pharmacol Ther       Date:  2020-07-20       Impact factor: 6.903

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.